Your browser doesn't support javascript.
loading
Management of Hypertension in Diabetic Kidney Disease.
Colbert, Gates B; Elrggal, Mohamed E; Gaddy, Anna; Madariaga, Hector M; Lerma, Edgar V.
Afiliação
  • Colbert GB; Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX 75246, USA.
  • Elrggal ME; Kidney and Urology Center, Alexandria 21922, Egypt.
  • Gaddy A; Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Madariaga HM; Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
  • Lerma EV; Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
J Clin Med ; 12(21)2023 Oct 31.
Article em En | MEDLINE | ID: mdl-37959333
Hypertension is a critical component of cardiovascular disease progression in patients with chronic kidney disease, and specifically diabetic kidney disease (DKD). Causation versus correlation remains up for debate, but what has been confirmed is the delay of DKD progression when hypertension is controlled or moved to guideline drive ranges. Many medications have been studied and used in real world experience for best outcomes, and we discuss below the proven winners thus far making up the renin angiotensin aldosterone system. As well, we discuss guideline changing medications including sodium-glucose cotransporter 2 inhibitors and newer generation mineralocorticoid receptor antagonists. With the growing prevalence of diabetes and DKD in the population, newer agents are emerging in multiple drug class and will be highlighted below. Clinicians continue to search for the optimal care plans for this challenging patient population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos